Role of the apoptotic and mitotic regulator survivin in melanoma.

Melanoma is the deadliest form of skin cancer. Melanoma develops in response to genetic and environmental pressures which lead to oncogenic transformation of normal human melanocytes, the pigment-producing cells in the body. The majority of melanoma-associated deaths are due to metastases, highlighting the importance of understanding the molecular mechanisms driving melanoma development and progression. This review focuses on survivin, and its involvement in the melanoma biology. Since its identification in the late 1990s, a vast body of work has been generated, demonstrating the role of survivin in various malignancies. This review discusses the established mitotic and cytoprotective properties of survivin, and its potential role in melanoma development and progression. A newly recognized functional property of survivin is also discussed, namely enhancement of cellular motility, which may underlie its role in promoting melanoma metastasis. Finally, various therapeutic strategies targeting survivin in melanoma are reviewed.

[1]  Pragna Patel,et al.  Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. , 2011, Journal of the American Academy of Dermatology.

[2]  Xuebiao Yao,et al.  Aurora B kinase activation requires survivin priming phosphorylation by PLK1. , 2011, Journal of molecular cell biology.

[3]  M. Sasamata,et al.  Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models , 2011, Cancer science.

[4]  Jonathan Chernoff,et al.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .

[5]  A. Ma,et al.  Histone deacetylation directs DNA methylation in survivin gene silencing. , 2011, Biochemical and biophysical research communications.

[6]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[7]  M. Ranson,et al.  Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study , 2010, Clinical Cancer Research.

[8]  D. Grossman,et al.  Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. , 2010, Cancer research.

[9]  M. P. Holloway,et al.  EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells , 2010, BMC Molecular Biology.

[10]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[11]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[12]  K. Garber.  Industry makes strides in melanoma , 2010, Nature Biotechnology.

[13]  S. Nieh,et al.  Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people. , 2010, European journal of dermatology : EJD.

[14]  L. Languino,et al.  IAP regulation of metastasis. , 2010, Cancer cell.

[15]  John Kirkwood,et al.  A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma , 2011, Investigational New Drugs.

[16]  M. Duffy,et al.  Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.

[17]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Chen,et al.  Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. , 2009, Human pathology.

[19]  M. Adamkov,et al.  Expression pattern of anti-apoptotic protein survivin in dysplastic nevi. , 2009, Neoplasma.

[20]  Alain C. Mita,et al.  Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics , 2008, Clinical Cancer Research.

[21]  Benjamin Frey,et al.  Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. , 2008, International journal of radiation oncology, biology, physics.

[22]  Aedín C Culhane,et al.  Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer , 2008, Clinical Cancer Research.

[23]  S. Srinivasula,et al.  IAPs: what's in a name? , 2008, Molecular cell.

[24]  M. Nasr,et al.  Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.

[25]  Fengzhi Li,et al.  Survivin repression by p53, Rb and E2F2 in normal human melanocytes. , 2008, Carcinogenesis.

[26]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[27]  J. Sampath,et al.  Alternative splice variants of survivin as potential targets in cancer. , 2007, Current drug discovery technologies.

[28]  R. Korneluk,et al.  Degradation of Survivin by the X-linked Inhibitor of Apoptosis (XIAP)-XAF1 Complex* , 2007, Journal of Biological Chemistry.

[29]  D. Rodriguez,et al.  E-Cadherin Is Required for Caveolin-1-Mediated Down-Regulation of the Inhibitor of Apoptosis Protein Survivin via Reduced β-Catenin-Tcf/Lef-Dependent Transcription , 2007, Molecular and Cellular Biology.

[30]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[31]  D. Altieri,et al.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. , 2007, Molecular cell.

[32]  U. Klein,et al.  Structure of a Survivin–Borealin–INCENP Core Complex Reveals How Chromosomal Passengers Travel Together , 2007, Cell.

[33]  S. Florell,et al.  Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. , 2007, Cancer research.

[34]  N. Zaffaroni,et al.  Targeting survivin in cancer therapy: fulfilled promises and open questions. , 2007, Carcinogenesis.

[35]  J. Swedlow,et al.  Phosphorylation by Aurora-B Negatively Regulates Survivin Function During Mitosis , 2007, Cell cycle.

[36]  I. Petersen,et al.  Nuclear export is essential for the tumor‐promoting activity of survivin , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  S. Wheatley,et al.  Separating the Anti-apoptotic and Mitotic Roles of Survivin* , 2006, Journal of Biological Chemistry.

[38]  N. London,et al.  Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist , 2006, Oncogene.

[39]  S. Leachman,et al.  Activation of dual apoptotic pathways in human melanocytes and protection by survivin. , 2006, The Journal of investigative dermatology.

[40]  Fengzhi Li,et al.  Survivin study: An update of “What is the next wave?” , 2006, Journal of cellular physiology.

[41]  D. Elashoff,et al.  Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine , 2005, International journal of cancer.

[42]  Jennifer J. Gibson,et al.  Pigmentary characteristics and moles in relation to melanoma risk , 2005, International journal of cancer.

[43]  A. Wickrema,et al.  Differential requirements for survivin in hematopoietic cell development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Colombo,et al.  Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.

[45]  S. Florell,et al.  Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi , 2005, Journal of cutaneous pathology.

[46]  D. Altieri,et al.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. , 2004, The Journal of clinical investigation.

[47]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[48]  John Calvin Reed,et al.  An IAP-IAP Complex Inhibits Apoptosis* , 2004, Journal of Biological Chemistry.

[49]  D. Hallahan,et al.  Nuclear survivin as a biomarker for non-small-cell lung cancer , 2004, British Journal of Cancer.

[50]  D. Grossman,et al.  Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells , 2004, Oncogene.

[51]  A. Winoto,et al.  Essential Role of Survivin, an Inhibitor of Apoptosis Protein, in T Cell Development, Maturation, and Homeostasis , 2004, The Journal of experimental medicine.

[52]  G. Linette,et al.  Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. , 2003, American journal of clinical pathology.

[53]  John Calvin Reed,et al.  HBXIP functions as a cofactor of survivin in apoptosis suppression , 2003, The EMBO journal.

[54]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[55]  M. Daidone,et al.  Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. , 2003, The Journal of investigative dermatology.

[56]  L. Frati,et al.  Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Altieri,et al.  Survivin in apoptosis control and cell cycle regulation in cancer. , 2003, Progress in cell cycle research.

[58]  M. Ikeguchi,et al.  survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma , 2002, British Journal of Cancer.

[59]  Jian Kuang,et al.  Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. , 2002, Molecular biology of the cell.

[60]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[61]  G. Giaccone,et al.  CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. , 2002, Experimental cell research.

[62]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[63]  D. Altieri,et al.  Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. , 2002, Journal of cell science.

[64]  M. Daidone,et al.  Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. , 2002, The Journal of clinical investigation.

[65]  S. Fukuda,et al.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. , 2001, Blood.

[66]  W. Sessa,et al.  Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. , 2001, The American journal of pathology.

[67]  D. Altieri,et al.  Inhibition of melanoma tumor growth in vivo by survivin targeting. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Downward,et al.  The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. , 2000, Journal of cell science.

[69]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Vaux,et al.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype , 2000, Current Biology.

[71]  H. Tsao.  Update on familial cancer syndromes and the skin. , 2000, Journal of the American Academy of Dermatology.

[72]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[73]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[74]  Fengzhi Li,et al.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function , 1999, Nature Cell Biology.

[75]  D. Altieri,et al.  Transcriptional analysis of human survivin gene expression. , 1999, The Biochemical journal.

[76]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[77]  D. Altieri,et al.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[78]  A. MacKenzie,et al.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.

[79]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.